Plenty of run left in Genetic Signatures
Less than a fortnight ago Finfeed noted Genetic Signature Ltd’s (ASX: GSS) news that it had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.
Management also noted at the time that it had submitted a formal application for European CE-IVD registration for a new real-time PCR (polymerase chain reaction).
I saw these developments as particularly significant for the company, and indeed shares in the company surged on the day the news was released.
There has been continual strong news flow from the company, as it received CE-IVD registration for its SARS-CoV-2 Detection Kit, as well as notification from the Therapeutic Goods Administration (TGA) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.
Not surprisingly, this has provided significant share price momentum, and since the company first came under Finfeed’s spotlight its shares have increased from $1.10 to $2.08.
Bell Potter sees upside of 25%
Bell Potter analyst Tanushree Jain likes the story, and just last week he upgraded his price target from $1.50 to $2.60 saying, ‘’March quarter 2020 revenue of $1.8 million (up 71% year-on-year), set a new record for GSS.
‘’The increase was driven by initial sales of GSS’ COVID-19 testing kit in Australia and the European Union (under regulatory exemptions).
‘’Formal regulatory approvals in the European Union and Australia for the kit were received in April.
‘’All indications are that the three months to June 30, 2020 will be another record quarter (Bell Potter estimates revenues of $5 million), with indicative revenue for Apr’20 alone at $1.7 million.’’
Consequently, while the company’s shares have had a strong run, Hester still sees upside of 25% relative to Friday’s closing price of $2.08.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.